KYMR Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2019βFY2025
Kymera Therapeutics, Inc. had $39.2M of revenue in fiscal 2025, down 16.7% on the year before. Over five years, revenue changed +2.9% a year on average.
Last close Β· Oct 23, 2026
$110.76
0.1%Hi! I read Kymera Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β16.7%
No. Sales fell 16.7% last year.
Does it make a profit?
β794.0%
No. It lost money last year.
Does profit turn into cash?
β597.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Kymera Therapeutics, Inc. had $39.2M of revenue in fiscal 2025, down 16.7% on the year before. Over five years, revenue changed +2.9% a year on average. Its operating margin was β891.1%, down 335.3Β pts: of every 100 in sales, about β891 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Kymera Therapeutics, Inc. lost $311M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$234M in fiscal 2025, β597.6% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $172M and sold $467M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$172M
1 insider
Sold, 12 months
$467M
11 insiders
Of sales under plans
57%
$268M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 30,000 | $113.80 | $3.4M | Form 4 |
| Sep 4, 2026 | Brian AdamsChief Legal Officer | Sold | 6,371 | $116.83 | $0.7M | Form 4 |
| Jul 7, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 50,000 | $119.00 | $6.0M | Form 4 |
| Jul 1, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 80,000 | $115.30 | $9.2M | Form 4 |
| Jul 1, 2026 | Noah GoodmanChief Business Officer | Sold plan | 3,389 | $114.29 | $0.4M | Form 4 |
| Jun 30, 2026 | Bruce N. JacobsChief Financial Officer | Sold plan | 77,109 | $114.97 | $8.9M | Form 4 |
| Jun 29, 2026 | Bruce BoothDirector | Sold plan | 31,283 | $109.48 | $3.4M | Form 4 |
| Jun 29, 2026 | Bruce BoothDirector | Sold plan | 45,367 | $107.06 | $4.9M | Form 4 |
| Jun 26, 2026 | Biotechnology Value Fund II LPDirector, See Remarks and Footnotes | Sold | 1,630,658 | $106.50 | $174M | Form 4 |
| Jun 26, 2026 | Bruce BoothDirector | Sold plan | 467,878 | $110.29 | $51.6M | Form 4 |
| Jun 25, 2026 | Noah GoodmanChief Business Officer | Sold plan | 5,000 | $114.00 | $0.6M | Form 4 |
| Jun 25, 2026 | Bruce BoothDirector | Sold plan | 285,684 | $121.86 | $34.8M | Form 4 |
| Jun 25, 2026 | Bruce BoothDirector | Sold plan | 262,637 | $115.39 | $30.3M | Form 4 |
| Jun 24, 2026 | Bruce BoothDirector | Sold plan | 134,720 | $100.51 | $13.5M | Form 4 |
| Jun 23, 2026 | Bruce BoothDirector | Sold plan | 1,408 | $99.98 | $0.1M | Form 4 |
| Jun 22, 2026 | Noah GoodmanChief Business Officer | Sold plan | 2,500 | $99.00 | $0.2M | Form 4 |
| Jun 22, 2026 | Bruce BoothDirector | Sold plan | 31,798 | $103.75 | $3.3M | Form 4 |
| Jun 22, 2026 | Bruce BoothDirector | Sold plan | 246,330 | $98.52 | $24.3M | Form 4 |
| Jun 18, 2026 | Bruce BoothDirector | Sold plan | 115,056 | $91.01 | $10.5M | Form 4 |
| Jun 17, 2026 | Bruce BoothDirector | Sold plan | 116,812 | $90.34 | $10.6M | Form 4 |
| May 27, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 4,279 | $81.58 | $0.3M | Form 4 |
| May 26, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 12,905 | $79.36 | $1.0M | Form 4 |
| May 11, 2026 | Elena RidloffDirector | Sold plan | 3,000 | $87.00 | $0.3M | Form 4 |
| Apr 29, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 30,000 | $81.18 | $2.4M | Form 4 |
| Apr 22, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 300 | $90.00 | $0.0M | Form 4 |
| Apr 22, 2026 | Bruce BoothDirector | Sold plan | 6,000 | $89.96 | $0.5M | Form 4 |
| Apr 15, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 1,300 | $90.00 | $0.1M | Form 4 |
| Apr 15, 2026 | Bruce BoothDirector | Sold plan | 5,335 | $90.04 | $0.5M | Form 4 |
| Apr 14, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 5,251 | $90.00 | $0.5M | Form 4 |
| Apr 14, 2026 | Noah GoodmanChief Business Officer | Sold plan | 1,347 | $90.00 | $0.1M | Form 4 |
| Apr 14, 2026 | Bruce BoothDirector | Sold plan | 4,159 | $89.97 | $0.4M | Form 4 |
| Apr 10, 2026 | Noah GoodmanChief Business Officer | Sold plan | 2,000 | $87.35 | $0.2M | Form 4 |
| Apr 9, 2026 | Noah GoodmanChief Business Officer | Sold plan | 8,264 | $87.50 | $0.7M | Form 4 |
| Apr 1, 2026 | Elena RidloffDirector | Sold plan | 4,600 | $85.41 | $0.4M | Form 4 |
| Apr 1, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 14,640 | $85.46 | $1.3M | Form 4 |
| Mar 31, 2026 | Elena RidloffDirector | Sold plan | 7,400 | $85.37 | $0.6M | Form 4 |
| Mar 31, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 7,600 | $85.38 | $0.6M | Form 4 |
| Mar 25, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 24,727 | $80.26 | $2.0M | Form 4 |
| Mar 23, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 91,250 | $77.41 | $7.1M | Form 4 |
| Mar 20, 2026 | Pamela EspositoDirector | Sold plan | 2,500 | $79.15 | $0.2M | Form 4 |
| Mar 11, 2026 | Jeremy G ChadwickChief Operating Officer | Sold plan | 25,758 | $83.30 | $2.1M | Form 4 |
| Mar 4, 2026 | Jeremy G ChadwickChief Operating Officer | Sold | 3,919 | $85.30 | $0.3M | Form 4 |
| Mar 4, 2026 | Bruce N. JacobsChief Financial Officer | Sold | 4,895 | $85.30 | $0.4M | Form 4 |
| Mar 4, 2026 | Jared GollobChief Medical Officer | Sold | 4,895 | $85.30 | $0.4M | Form 4 |
| Mar 2, 2026 | Bruce N. JacobsChief Financial Officer | Sold | 7,576 | $88.93 | $0.7M | Form 4 |
| Mar 2, 2026 | Bruce BoothDirector | Sold plan | 81,866 | $90.13 | $7.4M | Form 4 |
| Mar 2, 2026 | Jared GollobChief Medical Officer | Sold | 5,613 | $88.93 | $0.5M | Form 4 |
| Mar 2, 2026 | Jeremy G ChadwickChief Operating Officer | Sold | 2,039 | $88.93 | $0.2M | Form 4 |
| Feb 25, 2026 | Nello MainolfiChief Executive Officer, Director | Sold plan | 30,000 | $90.26 | $2.7M | Form 4 |
| Feb 20, 2026 | Pamela EspositoDirector | Sold plan | 2,500 | $87.31 | $0.2M | Form 4 |
| Jan 20, 2026 | Pamela EspositoDirector | Sold plan | 5,500 | $67.91 | $0.4M | Form 4 |
| Dec 31, 2025 | Nello MainolfiChief Executive Officer, Director | Sold plan | 30,000 | $78.06 | $2.3M | Form 4 |
| Dec 17, 2025 | Pamela EspositoDirector | Sold plan | 27,563 | $82.16 | $2.3M | Form 4 |
| Dec 12, 2025 | Bruce BoothDirector | Sold | 678 | $91.04 | $0.1M | Form 4 |
| Dec 11, 2025 | Bruce BoothDirector | Sold | 6,101 | $91.23 | $0.6M | Form 4 |
| Dec 11, 2025 | Felix BakerDirector, 10% owner | Bought | 2,005,813 | $86.00 | $172M | Form 4 |
| Dec 10, 2025 | Bruce BoothDirector | Sold | 229,809 | $91.73 | $21.1M | Form 4 |
| Dec 8, 2025 | Jared GollobChief Medical Officer | Sold plan | 49,307 | $88.66 | $4.4M | Form 4 |
| Dec 8, 2025 | Nello MainolfiChief Executive Officer, Director | Sold plan | 100,000 | $89.17 | $8.9M | Form 4 |
| Dec 8, 2025 | Jeffrey W. AlbersDirector | Sold plan | 5,000 | $89.76 | $0.4M | Form 4 |
| Oct 29, 2025 | Nello MainolfiChief Executive Officer, Director | Sold plan | 30,000 | $60.99 | $1.8M | Form 4 |
| Oct 15, 2025 | Jared GollobChief Medical Officer | Sold plan | 59,576 | $61.42 | $3.7M | Form 4 |
| Oct 13, 2025 | Jared GollobChief Medical Officer | Sold plan | 3,114 | $60.00 | $0.2M | Form 4 |
| Oct 13, 2025 | Jeffrey W. AlbersDirector | Sold plan | 5,000 | $59.19 | $0.3M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Kymera Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $442M | $407M | $375M | $489M | $848M |
| Current ratio | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
| Quick ratio | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
| Total assets | $606M | $603M | $576M | $978M | $1.7B |
| Total liabilities | $146M | $113M | $181M | $142M | $163M |
| Shareholders' equity | $460M | $490M | $395M | $836M | $1.6B |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Kymera Therapeutics, Inc. passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 7 | 2 / 7 | 2 / 7 | 3 / 8 | 3 / 8 | 3 / 8 |
| Accruals ratio | β50.7% | β44.3% | 5.3% | β0.3% | β7.5% | β3.8% | β5.8% |
| Altman Z'' | β2.24 | 2.55 | 4.84 | 4.47 | 1.00 | 4.82 | 9.79 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross profit | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $37.2M | $62.1M | $137M | $164M | $189M | $240M | $317M |
| Operating income | β$42.2M | β$46.3M | β$101M | β$161M | β$166M | β$262M | β$349M |
| Pretax income | β | β | β | β | β | β | β$311M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | β | β | $0.0M |
| Net income | β$41.2M | β$45.6M | β$100M | β$155M | β$147M | β$224M | β$311M |
| Net income to common | β$41.2M | β$54.6M | β$100M | β$155M | β$147M | β$224M | β$311M |
| Diluted EPS | β$24.28 | β$3.15 | β$2.09 | β$2.87 | β$2.52 | β$2.98 | β$3.69 |
| Diluted shares | 0.00B | 0.02B | 0.05B | 0.05B | 0.06B | 0.08B | 0.08B |
| Cash flow | |||||||
| Cash from operations | $17.9M | $88.1M | β$129M | β$153M | β$103M | β$195M | β$233M |
| Capital expenditure | $0.5M | $9.1M | $1.6M | $2.8M | $34.5M | $12.8M | $1.4M |
| Free cash flow | $17.4M | $79.0M | β$131M | β$156M | β$137M | β$207M | β$234M |
| Depreciation and amortization | $0.8M | $1.8M | $2.4M | $3.0M | $3.6M | $7.4M | $8.3M |
| Stock-based compensation | $1.2M | $5.2M | $25.0M | $35.5M | $43.1M | $55.0M | $59.9M |
| Balance sheet | |||||||
| Cash and short-term investments | $92.0M | $296M | $442M | $407M | $375M | $489M | $848M |
| Finance lease liabilities | β | $1.3M | $2.3M | $2.7M | $2.6M | $3.7M | $3.3M |
| Current assets | $92.8M | $302M | $451M | $419M | $405M | $510M | $871M |
| Current liabilities | $34.6M | $111M | $92.5M | $71.3M | $85.7M | $67.8M | $83.2M |
| Property and equipment, net | $3.8M | $10.8M | $11.9M | $13.3M | $48.1M | $50.5M | $43.2M |
| Total assets | $117M | $487M | $606M | $603M | $576M | $978M | $1.7B |
| Total liabilities | $82.0M | $203M | $146M | $113M | $181M | $142M | $163M |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M |
| Shareholders' equity | β$74.4M | $284M | $460M | $490M | $395M | $836M | $1.6B |
| Margins | |||||||
| Gross margin | β | β | β | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating margin | β1,438.5% | β136.1% | β138.0% | β344.4% | β210.6% | β555.8% | β891.1% |
| EBITDA margin | β1,410.4% | β130.9% | β134.7% | β338.0% | β206.1% | β540.2% | β869.9% |
| Net margin | β1,405.8% | β134.0% | β137.6% | β330.6% | β187.0% | β475.6% | β794.0% |
| FCF margin | 592.1% | 232.2% | β179.2% | β333.0% | β174.7% | β440.5% | β597.6% |
| Returns | |||||||
| Return on capital employed | β51.4% | β12.3% | β19.6% | β30.3% | β33.8% | β28.7% | β21.1% |
| Return on equity | β | β43.5% | β27.0% | β32.6% | β33.2% | β36.4% | β25.8% |
| Return on assets | β35.3% | β15.1% | β18.3% | β25.6% | β24.9% | β28.8% | β22.9% |
| Return on tangible equity | β | β19.2% | β21.8% | β31.6% | β37.2% | β26.8% | β19.7% |
| Growth | |||||||
| Revenue growth | β | 1,060.0% | 114.0% | β35.7% | 67.8% | β40.1% | β16.7% |
| FCF growth | β | 354.9% | β265.2% | β | β | β | β |
| Share count change | β | 921.5% | 176.6% | 12.4% | 8.2% | 28.6% | 12.6% |
| Financial health | |||||||
| Current ratio | 2.7x | 2.7x | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
| Quick ratio | 2.7x | 2.7x | 4.9x | 5.9x | 4.7x | 7.5x | 10.5x |
| Capital allocation | |||||||
| Capex / revenue | 18.1% | 26.7% | 2.2% | 6.1% | 43.9% | 27.3% | 3.7% |
| Stock comp / revenue | 40.8% | 15.2% | 34.3% | 75.8% | 54.9% | 116.9% | 152.8% |
| Quality scores | |||||||
| Piotroski F-score | β | 5.0 | 2.0 | 2.0 | 3.0 | 3.0 | 3.0 |
| Altman Z'' | β2.2 | 2.5 | 4.8 | 4.5 | 1.0 | 4.8 | 9.8 |
| Accruals ratio | β50.7% | β44.3% | 5.3% | β0.3% | β7.5% | β3.8% | β5.8% |
Source: SEC EDGAR XBRL filings (CIK 0001815442). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
